A Fluorescent Silver(I) Carbene Complex with Anticancer Properties: Synthesis, Characterization, and Biological Studies

The silver(I) NHC (N-heterocyclic carbene) complex bis(1(anthracen-9-ylmethyl)-3-ethylimidazol-2-ylidene) silver chloride, ([Ag(EIA)2]Cl) hereafter, bearing two anthracenyl fluorescent probes has been synthesized and characterised. [Ag(EIA)2]Cl is stable in organic solvents and under physiological-like conditions, and shows potent cytotoxic effects in vitro toward human SH-SY5Y neuroblastoma cells. The interactions of [Ag(EIA)2]Cl with a few model biological targets have been studied here as well as its ability to be internalized in cells. The in vitro anticancer activity is apparently related to the level of drug internalisation. Notably, [Ag(EIA)2]Cl does not react with a few model proteins, but is capable to bind the Cterminal dodecapeptide of thioredoxin reductase hTrxR(488-499). Binding occurs through an unconventional process leading to covalent binding of one or two carbene ligands to the C-terminal dodecapeptide with concomitant release of the silver cation. This mode of interaction, to the best of our knowledge, is reported here for the first time for Ag(NHC)2 complexes; consequently, a potent enzyme inhibition is measured.

The silver(I) N-heterocyclic carbene (NHC) complex bis(1-(anthracen-9-ylmethyl)-3-ethylimidazol-2-ylidene) silver chloride ([Ag(EIA) 2 ]Cl), bearing two anthracenyl fluorescent probes, has been synthesized and characterized. [Ag(EIA) 2 ]Cl is stable in organic solvents and under physiological conditions, and shows potent cytotoxic effects in vitro toward human SH-SY5Y neuroblastoma cells. The interactions of [Ag(EIA) 2 ]Cl with a few model biological targets have been studied as well as its ability to be internalized in cells. The in vitro anticancer activity is apparently related to the level of drug internalization. Notably, [Ag(EIA) 2 ]Cl does not react with a few model proteins, but is capable of binding the C-terminal dodecapeptide of thioredoxin reductase hTrxR(488–499) and to strongly inhibit the activity of this enzyme. Binding occurs through an unconventional process leading to covalent binding of one or two carbene ligands to the C-terminal dodecapeptide with concomitant release of the silver cation. To the best of our knowledge, this mode of interaction is reported here for the first time for Ag(NHC) 2 complexes.